Trastuzumab Increases Cardiotoxicity in Breast Cancer Patients

Share this content:

(ChemotherapyAdvisor) – Treatment of breast cancer patients with regimens containing trastuzumab increases their risk of cardiotoxicity, according to researchers of the University of Milan, Italy. The study, entitled “Trastuzumab-Containing Regimens for Early Breast Cancer,” was published in the online edition of The Cochrane Library on April 18. 

The primary aim of this study is assessment of efficacy and safety data for trastuzumab, when used alone or in combination with standard chemotherapy, for the treatment of HER2-positive early stage breast cancer. For the assessment, the authors searched the Cochrane Breast Cancer Group's (CBCGs) Specialized Trials Register to search, in several databases, for randomized controlled trials (RCTs) occurring prior to February 2010.

Data were collected from published and unpublished RCTs and used to calculate hazard ratios (HRs) for time-to-event outcomes and risk ratio (RRs) for outcomes; further analyses within subgroups included duration (less or greater than six months) and concurrent or sequential trastuzumab administration. Eight studies, involving 11,991 patients, were selected for analysis.

The authors reported that the “combined HRs for overall survival (OS) and disease-free survival (DFS) significantly favored the trastuzumab-containing regimens (HR=0.66; 95% confidence interval (CI) 0.57 to 0.77, P<0.00001; and HR=0.60; 95% CI 0.50 to 0.71, P<0.00001, respectively). Trastuzumab significantly increased the risk of congestive heart failure (RR=5.11; 90% CI 3.00 to 8.72, P<0.00001); and left ventricular ejection fraction decline (RR=1.83; 90% CI 1.36 to 2.47, P=0.0008).”

The authors concluded: “Trastuzumab significantly improves OS and DFS in HER2-positive women with early and locally advanced breast cancer, although it also significantly increases the risk of CHF and LVEF decline. Shorter duration of therapy may reduce cardiotoxicity and maintain efficacy…”

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs